About: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Creator	Wang, Bo Merad, Miriam Valle, Del Chari, Ajai Cho, Hearn Gnjatic, Sacha Jagannath, Sundar Madduri, Deepu Mouhieddine, Tarek Parekh, Samir Richard, Shambavi Richter, Joshua Van Oekelen, Oliver Marie, Diane
Source	Medline; PMC
abstract	BACKGROUND: The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the USA. Our institution has treated over 2000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma (MM) population. Herein, we report the characteristics of COVID-19 infection and serological response in MM patients in a large tertiary care institution in New York. METHODS: We performed a retrospective study on a cohort of 58 patients with a plasma-cell disorder (54 MM, 4 smoldering MM) who developed COVID-19 between March 1, 2020, and April 30, 2020. We report epidemiological, clinical, and laboratory characteristics including the persistence of viral detection by polymerase chain reaction (PCR) and anti-SARS-CoV-2 antibody testing, treatments initiated, and outcomes. RESULTS: Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age was 67 years; 52% of patients were male and 63% were non-White. Hypertension (64%), hyperlipidemia (62%), obesity (37%), diabetes mellitus (28%), chronic kidney disease (24%), and lung disease (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age (> 70 years), male sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (p < 0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (p < 0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia, non-White race, and mortality. Ninety-six percent (22/23) of patients developed antibodies to SARS-CoV-2 at a median of 32 days after initial diagnosis. The median time to PCR negativity was 43 (range 19–68) days from initial positive PCR. CONCLUSIONS: Drug exposure and MM disease status at the time of contracting COVID-19 had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia was associated with higher mortality. The majority of patients mounted an antibody response to SARS-CoV-2. These findings pave a path to the identification of vulnerable MM patients who need early intervention to improve outcomes in future outbreaks of COVID-19.
has issue date	2020-07-14(xsd:dateTime)
bibo:doi	10.1186/s13045-020-00934-x
bibo:pmid	32664919
has license	cc-by
sha1sum (hex)	28ecacb70247f4fb6a4923a99d0905153c23f88a
schema:url	https://doi.org/10.1186/s13045-020-00934-x
resource representing a document's title	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
has PubMed Central identifier	PMC7359431
has PubMed identifier	32664919
schema:publication	J Hematol Oncol
resource representing a document's body	covid:28ecacb70247f4fb6a4923a99d0905153c23f88a#body_text
is schema:about of	named entity 'antibody testing' named entity 'polymerase' named entity 'New York City' named entity 'The' named entity 'infection' named entity 'serological' named entity 'treated' named entity 'myeloma' named entity 'patients' named entity 'myeloma' named entity 'MULTIPLE MYELOMA' named entity 'USA' named entity 'PCR' named entity 'patients' named entity 'large' named entity 'tertiary care' named entity 'USA' named entity 'detection' named entity 'cancer care' named entity 'disorder' named entity 'Our' named entity 'developed' named entity 'infection' named entity 'Mount Sinai Hospital' named entity 'SARS-CoV-2 virus' named entity 'serological' named entity 'antibody testing' named entity 'IL-1β' named entity 'Good Clinical Practice' named entity 'cancer center' named entity 'Mount Sinai Hospital' named entity 'titer' named entity 'coronavirus disease 2019' named entity 'higher risk' named entity 'CRS' named entity 'Department of Microbiology' named entity 'COVID' named entity 'major bleeding' named entity 'ISS' named entity 'univariate analysis' named entity 'IL-6' named entity 'vancomycin' named entity 'mechanical ventilation' named entity 'aspirin' named entity '1.2' named entity 'Antibody titer' named entity 'remdesivir' named entity 'ISS' named entity 'death rates' named entity 'retrospective study' named entity 'COVID' named entity 'heart rate' named entity 'supplemental oxygen' named entity 'enoxaparin' named entity 'COVID' named entity '1:160' named entity 'polymerase chain reaction' named entity 'statistically significant' named entity 'anti-IL-6' named entity 'fever' named entity 'SARS-CoV-2' named entity 'death rate' named entity 'IMWG' named entity 'intubated' named entity 'ICU' named entity 'PCR' named entity 'selinexor' named entity 'inflammatory cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software